Biopharmaceutical company Amgen (NASDAQ:AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th ...

Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2024 results , with sales up 10.9% year on year to $9.09 billion. The ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

Analysts estimated Q4 adjusted EPS of $5.08 and revenue of $8.88 billion, but Amgen reported $5.31 in EPS and $9.1 billion in revenue, showcasing double-digit year-on-year growth in both metrics.

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...

Amgen exceeded analysts' revenue expectations this quarter, and its full-year revenue guidance came in slightly higher than Wall Street's estimates. On the other hand, its full-year EPS guidance ...

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

Wall Street expects the company to report a 7.9% increase in earnings per share to $5.08, on a revenue of $8.87B, up 8.2% from last year. Analysts at BMO Capital Markets expect Amgen’s 2025 ...

Revenue rose to $9.1 billion, outpacing the estimated $8.88 billion, up 11% year over year. Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong ...